Skip to main content


for people ages 55–85 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.

Official Title

A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease


Alzheimer's Disease Early Alzheimer's Disease Mild Cognitive Impairment (MCI) Mild Alzheimer's Disease (AD) Tau Early dementia Tauopathies AD Neurodegenerative diseases Memory loss Nervous system diseases Alzheimer Disease


You can join if…

Open to people ages 55–85

  • Subject who meets the National Institute on Aging and the Alzheimer's Association(NIA-AA) clinical criteria for mild cognitive impairment or probable AD, and have:
  • Clinical Dementia Rating (CDR)-Global Score of 0.5
  • Mini-Mental State Examination (MMSE) score of 22 to 30, inclusive
  • Repeatable Battery for the Assessment of Neuropsychological Status-Delayed Memory Index (RBANS - DMI) score of 85 or lower
  • Subject has a positive amyloid Positron Emission Tomography (PET) scan.
  • Subject has a Modified Hachinski Ischemic Scale (MHIS) score of ≤ 4.
  • The subject has an identified, reliable, study partner (e.g., family member).
  • If using medications to treat symptoms related to AD, doses must be stable for at least 12 weeks prior to randomization.

You CAN'T join if...

  • Subject has any contraindications or inability to tolerate to brain magnetic resonance imaging (MRI), PET scans or lumbar puncture.
  • Subject has evidence of any other clinically significant neurological disorder other than Early AD.
  • In the opinion of the investigator, the subject has any clinically significant or uncontrolled medical or psychiatric illness, or has had an infection requiring medical intervention in the past 30 days.
  • Subject has had a myocardial infarction, unstable angina, stroke, transient ischemic attack or required intervention for any of these conditions within 6 months of Screening.


  • Univ California, San Francisco accepting new patients
    San Francisco, California, 94143-2204, United States
  • Irvine Clinical Research accepting new patients
    Irvine, California, 92614, United States


accepting new patients
Start Date
Completion Date
Phase 2
Lead Scientist
Richard Tsai
Study Type
Last Updated
March 7, 2018
I’m interested in this study!